EyePoint (EYPT) EBITDA Margin (2010 - 2026)
EyePoint (EYPT) posted EBITDA Margin of 12532.47% for Q1 2026, down 10.46% sequentially from 11345.97% in Q4 2025, and down 1233275.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) EBITDA Margin (2010 - 2026) Analysis & Trends
EyePoint has reported EBITDA Margin for 17 years, with the latest figure at 12532.47% in Q1 2026.
- Quarterly EBITDA Margin fell 1233275.0% year-over-year to 12532.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3700.89% (down 341295.0% YoY) and the FY2025 annual result came in at 775.98%, down 43893.0% from the prior year.
- EBITDA Margin retreated to 12532.47% in Q1 2026 per EYPT's latest filing, from 11345.97% in the prior quarter.
- Over five years, EBITDA Margin peaked at 94.71% in Q3 2023 and troughed at 12532.47% in Q1 2026.
- A 5-year average of 2042.4% and a median of 285.18% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin jumped 29864 bps in 2023, then sank 1233275 bps in 2026.
- Over 5 years, EBITDA Margin stood at 415.22% in 2022, then jumped by 72 bps to 116.58% in 2023, then sank by 235 bps to 390.4% in 2024, then tumbled by 2806 bps to 11345.97% in 2025, then slipped by 10 bps to 12532.47% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 12532.47%, 11345.97%, and 6420.81% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -19,207.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19,207.10% |
| Mar 31, 2026 | -12,532.47% |
| Dec 31, 2025 | -11,345.97% |
| Sep 30, 2025 | -6,420.81% |
| Jun 30, 2025 | -1,166.83% |
| Mar 31, 2025 | -199.72% |
| Dec 31, 2024 | -390.40% |
| Sep 30, 2024 | -311.17% |
| Jun 30, 2024 | -364.52% |
| Mar 31, 2024 | -285.18% |
| Dec 31, 2023 | -116.58% |
| Sep 30, 2023 | -94.71% |
| Jun 30, 2023 | -249.98% |
| Mar 31, 2023 | -280.54% |
| Dec 31, 2022 | -415.22% |
| Sep 30, 2022 | -183.76% |
| Jun 30, 2022 | -166.16% |
| Mar 31, 2022 | -196.73% |
| Dec 31, 2021 | -156.36% |
| Sep 30, 2021 | -169.04% |